“

It is known that there are significant differences in the biology of the sexes and thus responses to same investigative drugs could be very different between a male animal vs a female animal, it is possible that compounds that failed to make it to the market due to failure of efficacy in the preclinical animals research stages, could have been effective therapies in women, or vice versa.